Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: Nature’s Way Licenses Chromax, Tauriga moves to supplements

This article was originally published in The Tan Sheet

Executive Summary

Nutrition 21, Nature’s Way settle patent case; Tauriga moves from food to supplements; Miami firm banned from weight loss market; national sales for Mary’s Nutritionals; and more news in brief.

You may also be interested in...



Pfizer Licenses Nutrition 21’s Chromax In Patent Claim Settlement

The settlement terms are confidential, but Pfizer “acknowledged the validity of Nutrition 21’s asserted patents” and the Centrum line “may continue to use chromium picolinate,” Nutrition 21 says. The firms agreed as attorneys prepared to begin questioning a pool of potential jurors for the trial.

ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?

AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.

ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer

While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel